These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 9129015

  • 1. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma--long-term results of a clinical trial.
    Hsu FJ, Caspar CB, Czerwinski D, Kwak LW, Liles TM, Syrengelas A, Taidi-Laskowski B, Levy R.
    Blood; 1997 May 01; 89(9):3129-35. PubMed ID: 9129015
    [Abstract] [Full Text] [Related]

  • 2. Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma.
    Davis TA, Hsu FJ, Caspar CB, van Beckhoven A, Czerwinsk DK, Liles TM, Taidi B, Benike CJ, Engleman EG, Levy R.
    Biol Blood Marrow Transplant; 2001 May 01; 7(9):517-22. PubMed ID: 11669219
    [Abstract] [Full Text] [Related]

  • 3. Upfront immunization with autologous recombinant idiotype Fab fragment without prior cytoreduction in indolent B-cell lymphoma.
    Navarrete MA, Heining-Mikesch K, Schüler F, Bertinetti-Lapatki C, Ihorst G, Keppler-Hafkemeyer A, Dölken G, Veelken H.
    Blood; 2011 Feb 03; 117(5):1483-91. PubMed ID: 21045197
    [Abstract] [Full Text] [Related]

  • 4. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.
    Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, Taidi B, Rajapaksa R, Caspar CB, Okada CY, van Beckhoven A, Liles TM, Engleman EG, Levy R.
    Blood; 2002 Mar 01; 99(5):1517-26. PubMed ID: 11861263
    [Abstract] [Full Text] [Related]

  • 5. Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression.
    Bertinetti C, Zirlik K, Heining-Mikesch K, Ihorst G, Dierbach H, Waller CF, Veelken H.
    Cancer Res; 2006 Apr 15; 66(8):4496-502. PubMed ID: 16618777
    [Abstract] [Full Text] [Related]

  • 6. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy.
    Massaia M, Borrione P, Battaglio S, Mariani S, Beggiato E, Napoli P, Voena C, Bianchi A, Coscia M, Besostri B, Peola S, Stiefel T, Even J, Novero D, Boccadoro M, Pileri A.
    Blood; 1999 Jul 15; 94(2):673-83. PubMed ID: 10397734
    [Abstract] [Full Text] [Related]

  • 7. Translational development of vaccination strategies in follicular NHL.
    Sakamaki I, Qin H, Kwak LW.
    Best Pract Res Clin Haematol; 2011 Jun 15; 24(2):295-304. PubMed ID: 21658625
    [Abstract] [Full Text] [Related]

  • 8. Therapeutic lymphoma vaccines: importance of T-cell immunity.
    Neelapu SS, Lee ST, Qin H, Cha SC, Woo AF, Kwak LW.
    Expert Rev Vaccines; 2006 Jun 15; 5(3):381-94. PubMed ID: 16827622
    [Abstract] [Full Text] [Related]

  • 9. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors.
    Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R.
    N Engl J Med; 1992 Oct 22; 327(17):1209-15. PubMed ID: 1406793
    [Abstract] [Full Text] [Related]

  • 10. Vaccine strategies in the treatment of low-grade non-Hodgkin lymphoma.
    Koumarianou A, Kountourakis P, Economopoulos T.
    J Steroid Biochem Mol Biol; 2008 Apr 22; 109(3-5):230-2. PubMed ID: 18406604
    [Abstract] [Full Text] [Related]

  • 11. Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a phase I clinical study.
    McCormick AA, Reddy S, Reinl SJ, Cameron TI, Czerwinkski DK, Vojdani F, Hanley KM, Garger SJ, White EL, Novak J, Barrett J, Holtz RB, Tusé D, Levy R.
    Proc Natl Acad Sci U S A; 2008 Jul 22; 105(29):10131-6. PubMed ID: 18645180
    [Abstract] [Full Text] [Related]

  • 12. Listeriolysin O is an improved protein carrier for lymphoma immunoglobulin idiotype and provides systemic protection against 38C13 lymphoma.
    Neeson P, Pan ZK, Paterson Y.
    Cancer Immunol Immunother; 2008 Apr 22; 57(4):493-505. PubMed ID: 17876582
    [Abstract] [Full Text] [Related]

  • 13. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
    Timmerman JM, Singh G, Hermanson G, Hobart P, Czerwinski DK, Taidi B, Rajapaksa R, Caspar CB, Van Beckhoven A, Levy R.
    Cancer Res; 2002 Oct 15; 62(20):5845-52. PubMed ID: 12384547
    [Abstract] [Full Text] [Related]

  • 14. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma.
    Schuster SJ, Neelapu SS, Gause BL, Janik JE, Muggia FM, Gockerman JP, Winter JN, Flowers CR, Nikcevich DA, Sotomayor EM, McGaughey DS, Jaffe ES, Chong EA, Reynolds CW, Berry DA, Santos CF, Popa MA, McCord AM, Kwak LW.
    J Clin Oncol; 2011 Jul 10; 29(20):2787-94. PubMed ID: 21632504
    [Abstract] [Full Text] [Related]

  • 15. Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId.
    Hurvitz SA, Timmerman JM.
    Expert Opin Biol Ther; 2005 Jun 10; 5(6):841-52. PubMed ID: 15952914
    [Abstract] [Full Text] [Related]

  • 16. Idiotype vaccines for non-Hodgkin's lymphoma induce polyclonal immune responses that cover mutated tumor idiotypes: comparison of different vaccine formulations.
    Caspar CB, Levy S, Levy R.
    Blood; 1997 Nov 01; 90(9):3699-706. PubMed ID: 9345055
    [Abstract] [Full Text] [Related]

  • 17. Effect of linkage of transduction domain sequences to a lymphoma idiotype DNA vaccine on vaccine effectiveness.
    Ashour AK, Petersen JL, McIlhaney MM, Vose JM, Solheim JC.
    Hybridoma (Larchmt); 2006 Oct 01; 25(5):306-8. PubMed ID: 17044787
    [Abstract] [Full Text] [Related]

  • 18. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma.
    Inogès S, Rodrìguez-Calvillo M, Zabalegui N, Lòpez-Dìaz de Cerio A, Villanueva H, Soria E, Suárez L, Rodríguez-Caballero A, Pastor F, García-Muñóz R, Panizo C, Pèrez-Calvo J, Melero I, Rocha E, Orfao A, Bendandi M, Grupo Español de Linfomas/Trasplante Autologo de Medula Oseo study group, Programa para el Estudio y Tratamiento de Hemopatias Malignas study group.
    J Natl Cancer Inst; 2006 Sep 20; 98(18):1292-301. PubMed ID: 16985248
    [Abstract] [Full Text] [Related]

  • 19. Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone.
    Davis TA, Maloney DG, Czerwinski DK, Liles TM, Levy R.
    Blood; 1998 Aug 15; 92(4):1184-90. PubMed ID: 9694706
    [Abstract] [Full Text] [Related]

  • 20. Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: the addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells.
    Maloney DG, Brown S, Czerwinski DK, Liles TM, Hart SM, Miller RA, Levy R.
    Blood; 1992 Sep 15; 80(6):1502-10. PubMed ID: 1520877
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.